Información del artículo
Resumen
En la Digestive Disease Week 2011 se han presentado numerosos estudios que muestran cómo todos los conceptos sobre enfermedad inflamatoria cambian a gran velocidad. Aunque se presta habitualmente más atención a los estudios sobre tratamiento, los cambios en las definiciones y en los procesos diagnósticos son, si cabe, más llamativos. Los estudios genéticos están empezando a delimitar subgrupos diferentes de pacientes. Cada vez son más los datos que demuestran que la mera evaluación clínica no es suficiente para estimar la situación real del paciente y que es necesario progresar tanto en los índices objetivos de actividad de la enfermedad (biomarcadores, técnicas de imagen, cuantificación y validación de los índices) como en completar las perspectivas definiendo las consecuencias económicas, personales y sociales de la enfermedad, así como valorando otros aspectos como los riesgos de otras afecciones, a veces consecuencia directa de los tratamientos.
Palabras clave:
Biomarcador
Calprotectina
Colitis ulcerosa
Diagnóstico
Ecografía
Endoscopia
Enfermedad de Crohn
Resonancia magnética
Abstract
A large number of new studies on all the concepts of inflammatory bowel disease were presented at Digestive Disease Week 2011, showing a rapidly changing scenario. Although therapeutic trials usually receive the lion's share of attention, the changes in definitions and diagnostic processes were, if anything, more striking. Genetic studies are starting to define new subgroups of patients. More and more data show that traditional clinical evaluation is insufficient to assess patients’ real status. Both objective indexes of disease activity (biomarkers, imaging techniques, quantification and validation of indexes) and new perspectives are required. These new perspectives include gaining greater insight into the economic, personal and social consequences of the disease, as well as assessing other issues such as the risks of other diseases, which are sometimes the direct consequence of treatments.
Keywords:
Biomarker
Calprotectin
Ulcerative colitis
Diagnosis
Ultrasound
Endoscopy
Crohn's disease
Magnetic resonance imaging
El Texto completo está disponible en PDF
Bibliografía
[1.]
M.E. Porter, E. Olmsted Teisberg.
Redefining health care. Creating value-based competition on results.
Harvard Business Review Press, (2006),
[2.]
B. Khor, A. Gardet, R.J. Xavier.
Genetics and pathogenesis of inflammatory bowel disease.
Nature, 474 (2011), pp. 307-317
[3.]
J. Essers, E.B. Cole, M. Dubinskiy, T. Haritunians, J. Korzenick, D.M. MacGovern, et al.
The utility of genetics in classifying ulcerative colitis and Crohn's disease.
Gastroenterology, 140 (2011), pp. S362-S363
[4.]
T. Zhang, Q. Gong, S.R. Hunt, R.D. Newberry, T. Dassopolus, W. Zhu, E. Li.
Multi-class classification analysis identifies an ileal gene signature that distinguishes between Crohn's disease, ulcerative colitis and control patients.
Gastroenterology, Suppl1 (2011), pp. S1052
[5.]
S. O’Donell, M. O'Sullivan, N. Breslin, H.J. O’Connor, C. O’Morain, P.L. Crotty, et al.
Isolated active ileitis: serological and genetic profile.
Gastroenterology, 140 (2011), pp. S1
[6.]
T. Melum, T. Folseraas, B.D. Juran, R.K. Weersma, T.J. Schramm, D. Gotthardt, et al.
Novel susceptibility loci for primary sclerosing colangitis identified by genome-wide association and replication analysis.
Gastroenterology, 140 (2011), pp. S77
[7.]
M. Dubinsky, S. Kugathasan, S. Kwon, T. Haritunians, I.T. Wrobel, G. Wahbeh, et al.
A combinantion of gentic, clinical, and immune markers predicts the need of surgery in Crohn's disease.
Gastroenterology, 140 (2011), pp. S230
[8.]
C. Siegel, P. Fleshner, L. Siegel, J. Rotter, M. Dubinsky, E. Vasiliauskas, et al.
Predicting Crohn's disease post-operative recurrence using clinical, endoscopic, serologiuc and genetic factors.
Gastroenterology, 140 (2011), pp. S230
[9.]
J.M. Choi, D.M. McGovern, E.S. Lee, D. Berel, S. Kwon, C.J. Landers, et al.
Predictors of therapeutic remission to thiopurines in pediatric inflammatory bowel disease.
Gastroenterology, 140 (2011), pp. S231
[10.]
M. Waterman, A. Dinani, W. Xu, J.M. Stempak, G. Nguyen, Z. Cohen, et al.
Clinical and genetic markers of disease prognosis in ulcerative colitis.
Gastroenterology, 140 (2011), pp. S231
[11.]
A.M. Phillips, I.D. Arnott, T. Heron, S. Cleary, C. Mowart, H. Clark, et al.
Clinical and genetic factors predict severe disease: a novel composite severity index.
Gastroenterology, 140 (2011), pp. S1143
[12.]
M. Chaparro, W. Zabala-Fernández, M. Barreir-De Acosta, J. Panés, M. Esteve, M. Andreu, et al.
New genetic associations detected in an exome-wide association sgtudy for toxicity related to thioopurine treatments in inflammatory bowel disease.
Gastroenterology, 140 (2011), pp. S365
[13.]
C.A. Siegel, S.M. Marden, C. Kozlowski, B.J. Loew, C. Levy, S.P. Bensen.
Crohn's disease patients report their definitions of “rare” adverse events, remission and the importance of mucosal healing: a quantitative and qualitative study of whta ptients really think.
Gastroenterology, 140 (2011), pp. S209
[14.]
J.E. Baars, V.J. Nuij, B. Oldenburg, E.J. Kuipers, C.J. Van der Woude.
The majority of patients with inflammatory bowel disease in clinical remission has mucosal inflammation.
Gastroenterology, 140 (2011), pp. S1136
[15.]
D. Rubin, P. Koduru, B. Surma, N. Hou.
Frequency of sub-clinical disease activity in ulcerative colitis patients.
Gastroenterology, 140 (2011), pp. S423-S424
[16.]
S. Wolff, G. Terheggen, R. Mueller, R. Greinwald, W. Kruis.
Are endoscopic assessments a reliable measure in trials of ulcerative colitis?.
Gastroenterology, 140 (2011), pp. S563
[17.]
A.D. Dhanda, T.J. Creed, R. Greenwood, B. Sands, C. Probert.
Can endoscopy be avoided in the assessment of ulcerative colitis in clinical trials.
Gastroenterology, 140 (2011), pp. S594-S595
[18.]
B. Lemmens, I. Arijs, G. Van Assche, P.J. Rutgeerts, K. Geboes, S. Vermeire, et al.
Correlation tbetween the endoscopic and histological score in assessing the activity of ulcerative colitis.
Gastroenterology, 140 (2011), pp. S595-S596
[19.]
S.P.L. Travis, P.D.R. Higgins, T. Orchard, C.J. Van der Woude, R. Panaccione, A. Bitton, et al.
Review article: defining remission in ulcerative colitis.
Aliment Pharmacol Ther, 34 (2011), pp. 113-124
[20.]
S. Samuel, E. Loftus, D.H. Bruining, K.T. Thia, W.J. Tremaine, K.W. Schroeder, et al.
Validation of the ulcerative colitis endoscopic index of severity (UCEIS) and its correlation with clinical incides and laboratory measures of disease activity.
Gastroenterology, 140 (2011), pp. S208
[21.]
M. DeVos, O. Dewit, G. D’Haens, F. Baert, F. Fontaine, S. Vermeire, et al.
Calprotectin as a biomarker for remission in UC Patients under IFX therapy.
Gastroenterology, 140 (2011), pp. S370
[22.]
C. Berger, S.M. Loitchs, F. Hartmann, A.U. Dignass, J. Stein.
Comparative evaluation of fecal calprotectin and S100A12 as non-invasive markers for disease activivity in Inflammatory Bowel Disease.
Gastroenterology, 140 (2011), pp. S605
[23.]
G. Chung-Faye, K. Sandhu, R.P. Logan, R.A. Sherwood.
Fecal calprotectin is strongly predictive of clinical disease activity and histological severity in inflammatory bowel disease.
Gastroenterology, 140 (2011), pp. S595
[24.]
W.J. Sandborn, J.F. Colombel, E. Louis, R. Panaccione, R. Thakkar, M.M. Castillo, et al.
Optimal C-reactive protein cutoff for predicting hospitalization in patients with moderately active Crohn's disease.
Gastroenterology, 140 (2011), pp. S595
[25.]
M. Chaparro, P. Miranda-García, J.P. Gisbert.
Correlation between serological biomarkers and clinical activity in patients with inflammatory bowel disease.
Gastroenterology, 140 (2011), pp. S599
[26.]
A. Bodelier, E. De Boer, D. Jonkers, W. Hameeteman, A. Masclee, M.J. Pierik.
Monitorin gisease activity in IBD: correlation between clinical activity índices and biomarkers.
Gastroenterology, 140 (2011), pp. S597
[27.]
P. Drastich, J. Kozeluhova, M. Jeresova, J. Spicak.
Infliximab trouhg levels and deep remission in patients with IBD.
Gastroenterology, 140 (2011), pp. S387
[28.]
D. Drobne, P. Bossuyrt, C. Breynaert, N.V. Castelee, G. Compernolle, M. Jügens, et al.
Crohn's disease: infliximab trough levels and CRP during infliximab-immunomodulator combination treatment are associated with clinical outcome after immunomodulator withdrawal.
Gastroenterology, 140 (2011), pp. S70
[29.]
F. Baert, D. Drobne, V. Ballet, I. Cleynen, G. Compernolle, P. Rutgeerts, et al.
Early trough levels and antibodies predict safety an success of restargting infliximab after long drug holiday.
Gastroenterology, 140 (2011), pp. S70
[30.]
A. Kaul, S. Hutfless, M.R. Marohn, M.X. Li.
Serum anti-glycan antibody biomarkers in inflammatory bowel disease diagnosis and progression: a meta-analysis.
Gastroenterology, 140 (2011), pp. S229
[31.]
J.P. Gisbert, F. Gomollón, J. Maté, J.M. Pajares.
Papel de los anticuerpos anticitoplasma de los neutrófilos (ANCA) y anti-Saccharomyces cerevisiase (ASCA) en la enfermedad inflamatoria intestinal.
Gastroenterol Hepatol, 26 (2003), pp. 312-324
[32.]
J. Markowitz, N.S. Leleiko, D.J. Keljo, D.R. Mack, J. Evans, M. Kappelman, et al.
The Prometheus Crohn's prognostic test does not reliably predict complicated Crohn's disease in children.
Gastroenterology, 140 (2011), pp. S230
[33.]
W. Blonski, M.T. Osterman, C.M. Brensinger, A.M. Buchner, G.R. Licchtenstein.
An update: which endoscopic or clinical factor is most predictive of future disesase course in patients with ulcerative colitis?.
Gastroenterology, 140 (2011), pp. S209
[34.]
W. Reinichs, P.J. Rutgeerts, J.F. Colombel, W.J. Sandborn, G.J. Mantzaris, A. Kornbluth, et al.
Association of steroid-free clinical remission and complete mucosal healing at 6 months with clinical oitcome at 1 year: a post-hoc analysisi of SONIC trial data.
Gastroenterology, 140 (2011), pp. S356
[35.]
J.A. Leighton, S.A. Cohen, E. Toth, D.R. Cave, D.C. Wolf, G.E. Mullin, et al.
A prospective multicenter blinded cohort study comparing diagnostic yield of capsule endoscopy(CE) prior to ileocolonoscopy (IC) compared to small bowel follow trough (SBFT) prior to IC in patientes with suspected Crohn's disease.
Gastroenterology, 140 (2011), pp. S208
[36.]
J. Panés, R. Bouzas, M. Chaparro, V. García-Sánchez, J.P. Gisbert, B. Martínez De Guereñu, et al.
Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease.
Aliment Pharmacol Ther, 34 (2011), pp. 125-145
[37.]
Hyun SB, Nagamuna M, Nagahori M, Fujii T, Watanabe M. MR enterocolonography demonstrates comparative ability to endoscopy for the simultaneous assessment of smalll and large intestinal lesions in Crohn's Disease. Gastroenterology. 1011; 140 Suppl 1:S84.
[38.]
I. Ordás, J. Rímola, T. Ripolles, O. García-Bosch, S. Rodríguez, C. Ayuso, et al.
Accuracy of MRI to assess therapeutic responses and mucosal healing in Crohn's disease.
Gastrotenterology, 140 (2011), pp. S85
[39.]
G.A. Van Assche, K.A. Hermann, E. Louis, S. Everett, J.F. Colombel, J.F. Rahier, et al.
Effects of infliximab therapy on transmural lesions assessed by MRI enteroclysis in patients with ileal Crohn's disease: the ACTIF study.
Gastroenterology, 140 (2011), pp. S85
[40.]
O.F. Craig, S.B. O’Neill, S. Leong, F. O’Neill, O.J. O’Connor, M.M. Maher, et al.
A prospective trial of low-dose abdominal computarized tomography (CT) with iterative reconstruction vs conventional CT in Crohn's disease.
Gastroenterology, 140 (2011), pp. S84
[41.]
R.O. Butcher, E. Nixon, C. Robertson, M. Sapundzieski, R. Filobbos, J.K. Limdi.
Diagnostic medical radiation in inflammatory bowel disease:primun non nocere?.
Gastroenterology, 140 (2011), pp. S1055
[42.]
E. Llano, J.G. Fletcher, J.L. Fidler, J.E. Huprich, E.V. Loftus, W.J. Sandborn, et al.
MR enterography for Crohn's disease: perfomance assessment in a large abdominal imaging practice.
Gastroenterology, 140 (2011), pp. S599
[43.]
B.G. Levesque, L.E. Cipriano, G. Zaric, W.J. Sandborn, E.V. Loftus.
Cost-effectiveness of computed tomographic enterography compared to magnetic resonance enterography in a simulated Medicare population with Crohn's disease.
Gastroenterology, 140 (2011), pp. S1053
[44.]
C. Randazzo, C. Rigazio, E. Ercole, M. Daperno, R. Sostegni, A. Lavagna, et al.
Ultrasonographic features predicting post-surgical recurrence in Crohn's disesase.
Gastroenterology, 140 (2011), pp. S599
[45.]
H. Neye, D. Ensberg, P. Rauh, U. Peitz, G. Treiber, P. Malfrtheiner, et al.
High end ultrasound with a high accuraccy in Crohn's disease complications.
Gastroetnerology, 140 (2011), pp. S601
[46.]
N. Pallotta, G. Vincoli, C. Montesani, P. Chirletti, A. Pronio, R. Caronna, et al.
Small intestine contrast ultrasonography (SICUS) inthe preoperative assessment of patients with Crohn's disease of the small bowel.
Gastroenterology, 140 (2011), pp. S1049
[47.]
E. Calabrese, F. Zorzi, S. Zuzzi, S. Oola, S. Onali, C. Petruzziello, et al.
Development of a quantitative sonographic lesionindex for small bowl Crohn's disease.
Gastroenterology, 140 (2011), pp. S1049
[48.]
M.D. Jensen, J. Kjeldsen, S.R. Rafaelsen, T. Nathan.
Low sensitiviities of MR and CT-enterography for detection of small bowel stenoses in patients with known Crohn's disease.
Gastroentrology, 140 (2011), pp. S1119-S1120
[49.]
R.W. Stidham, J. Xu, L. Johnson, K. Kim, J.M. Rubin, D. Moons, et al.
Ultrasound elasticity imaging can distinguish intestinal inflammation from fibrosis in the rat TNBS colitis model.
Gastroenterology, 140 (2011), pp. S84
[50.]
G.C. Nguyen, Z. Nugent, S.Y. Shaw, C.H.N. Bernstein.
A populationbased cohort analysis of risk of surgery, hospitalization and the use of immunomodulatory therapy for Crohn's disease over the last two decades: the impact of specisalist care.
Gastroenterology, 140 (2011), pp. S39
[51.]
G. Nguyen, Z. Nugent, S. Shaw, C.N. Bernstein.
Outcomes of patients with Crohn's disease improved from 1988 to 2008 and were associated with increased specialist care.
Gastroenterology, 141 (2011), pp. 90-97
[52.]
M. Van der Valk, M.J.J. Mangen, M.G. Van Oijen, P.D. Siersema, B. Oldenburg.
Work disability in Inflammatory Bowel Disease: first results from the COIN study.
Gastroenterology, 140 (2011), pp. S6
[53.]
L. Peyrin Biroulet, A. Cieza, W.J. Sandborn, M. Coenen, Y. Chowers, T. Hibi, et al.
Disabilituy in inflammatory bowel disease: developing Icf score sets for patients with inflammatory bowel disease based on the WHO international classifcation of disability and health.
Gastroenterology, 140 (2011), pp. S598
[54.]
F. Gomollón, Y. González-Lama, J. Hinojosa, M. Iglesias, M. Maroto, F. Muñoz, et al.
Health related quality of life, work productivity and psychological ell-being in Spanish Crohn disease patients.
Gastroenterology, 140 (2011), pp. S569
[55.]
D. Duricova, N. Pedersen, J. Burisch, M. Elkjaer, C. Dobrzanski, N.N. Andersen, et al.
Ehealth: impact of web-based treatment optimization solution (traffic light) on the quality of life in Crohn's disease patients treated with inflximab.
Gastroenterology, 140 (2011), pp. S298
[56.]
M. Eljkaer, M. Shuhaibar, J. Burisch, Y. Bailey, H. Scherfig, B. Laugesen, et al.
E-Health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided “constantcare” approach.
Gut, 59 (2010), pp. 1652-1661
[57.]
M. Kappelman, D.K. Farkas, R. Erichsen, L. Pedersen, R. Sandler, J.A. Baron, et al.
Risk of solid organ and hematological malignancy in patients with inflammatory bowel disease.
Gastroenterology, 140 (2011), pp. S45-S46
[58.]
L. Peyrin-Biroulet, K. Khosrotehrani, F. Carrat, A.M. Bouvier, J.B. Cheveaux, F. Carbonell, et al.
Risk of squamous and basal cell carcinoma in patients with inflammatory bowel diseases exposed to thiopurines: The CESAME national cohort study.
Gastroenterology, 140 (2011), pp. S46
[59.]
H. Sokol, L. Beaugerie, M. Maynadie, F. Carrat, N. Brousse.
Excess intestinal lymphoproliferative disorders in UBD.
Gastroenterology, 140 (2011), pp. S46
[60.]
D. Kotlyar, J.P. Gisbert, J.D. Lewis, C.M. Breninger, L. Beauerie, W. Blonski, et al.
A new meta-analysis of overall risk of lymphoma in patients with inflammatory bowel disease on thiopurine therapy: inclusión of the ENEIDA population study population from Spain, and differences between referral centers and population based studies.
Gastroenterology, 140 (2011), pp. S46
[61.]
D. Kotlyar, J.P. Gisbert, J.D. Lewis, C.M. Brensinger, L. Beaugerie, W. Blonski, et al.
Overall incidence of hepatosplenic T cell lymphoma in patients with infllamamtory bowel disease on thiopurines: meta-analysis of three population based studies.
Gastroenterology, 140 (2011), pp. S1135
[62.]
L. Mlodinov.
El andar del borracho.
Crítica, (2008),
[63.]
W. Afif, W.J. Sandborn, W.A. Faubieon, M. Rahman, W.S. Harmsen, A.R. Zinsmeister, et al.
Risk factors for lymphoma in patients with inflammatory bowel disease: a case-control study.
Gastroenterology, 140 (2011), pp. S46-S47
[64.]
F.D. Van Schalik, H.M. Smeets, G.J. Van der Heijden, P.D. Siersema, M.G.V. Oijen, B. Oldenburg.
Thiopurines prevent adavnced colorectal neoplasia in patients with inflammatory bowel disease.
Gastroenterology, 140 (2011), pp. S47
[65.]
J.F. Rahier, S. Ben-Horin, Y. Chowers, C. Conlon, P. DeMunier, G. D’Haens, et al.
European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.
J Crohns Colitis, 3 (2009), pp. 47-91
[66.]
C. Taxonera, M. Barceló, J.L. Mendoza, D.M. Cruz-Santamaría, C. Alba, N. López-Palacios, et al.
Serial tuberculin skin tests to detect latent tuberculosis in infllammatory bowel disease patinent receiving infliximab therapy.
Gastroenterology, 140 (2011), pp. S245
[67.]
M. Arias, R. De Francisco, S. Riestra, A. Pando, J.J. Palacios, P. Escalante, et al.
Perfomance of two interferón-gamma reléase assays (T-SPOT.TB and quantiferon-TB gold in tube) increase diagnostic yield of tuberculin skin testing for detection of latent tuberculosis in patients with inflammatory bowel diseases.
Gastroenterology, 140 (2011), pp. S1051
[68.]
P. Ministro, J. Machado, R. Araújo, A. Castanheira, E.M. Cancela, A. Silva.
Diagnosis of latent tuberculosis in patients with inflammatory bowel disease: prospective comparison between tuberculin skin test ant interferón gamma release assay (IGRA) test.
Gastroenterology, 140 (2011), pp. S1136
[69.]
N. Chaparro, A. Rodríguez Nogueiras, L.A. Menchen, I. Marín-Jiménez, V. García-Sánchez, J.R. Villagrasa, et al.
Comparative study to evaluate teh effectiveness of two different vaccination protocols against hepatitis B virus (HBV) in inflammatory bowel disease patients.
Gastroenterology, 140 (2011), pp. S868
[70.]
M. Chaparro, A. Rodríguez Nogueiras, J. Villagrasa, J.P. Gisbert.
Kinetics of the anti-HBs titers after vaccination against hepatitis B virus (VHB) in patients with inflammatory bowel disease (IBD).
Gastroenterology, 140 (2011), pp. S870
[71.]
G. Fiorino, P. Naccarato, H. Szabo, S. Vetrano, O. Sociale, A. Repici, et al.
Effect of immunosuppression on immune response to pneumococcal vaccine in inflammatory boel disease: a prospective study.
Gastroenterology, 140 (2011), pp. S244-S245
[72.]
J.Y. Chou, E. Vasiliauskas, E.J. Feldman, D. Berel, D.M. McGovern, A. Ippoliti, et al.
Immunosuprresion does not influence the decay of pneumococcal antibodies 3 years after vaccination in patients with inflammatory bowel disease.
Gastroenterology, 140 (2011), pp. S600-S601
[73.]
Y. Lu, L.A. Ashworth, A. Bousvaros, R. Carey, H.D. Renn, D.L. Jacobson.
Immune response to human paillomavirus vaccine (Gardasil) in girls and Young women with inflammatroy bowel disease.
Gastroenterology, 140 (2011), pp. S245
[74.]
G. Andrisani, D. Frasca, A. Armuzzi, A. Papa, M. Marzo, C. Felice, et al.
Response to influenza vaccine a/H1N1 2009 in patients with inflammatory bowel disease on antiTNF treatment.
Gastroenterology, 140 (2011), pp. S368
[75.]
I. Dotan, H. Shaharabani, R. Kariv, E. Tiommy, J. Pfefer, S. Fishmann, et al.
Influenza A H1N1 vaccine is safe and effective in patients with inflammatory bowel disease (IBD) treated with thioppurines and TNF blockers.
Gastroenterology, 140 (2011), pp. S1131-S1132
Copyright © 2011. Elsevier España S.L.. Todos los derechos reservados
